Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | May 8, 2008 | ||||
| Last Updated Date | April 19, 2011 | ||||
| Start Date ICMJE | June 2009 | ||||
| Primary Completion Date | April 2010 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
Plaque neovascularization at contrast-enhanced ultrasound and MRI [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ] | ||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | Complete list of historical versions of study NCT00677963 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation | ||||
| Official Title ICMJE | Contrast-enhanced Ultrasound and Magnetic Resonance Imaging for the Evaluation of Neovascularisation in Carotid Artery Plaques | ||||
| Brief Summary | The first goal of this study is to investigate whether CE-US is able to accurately identify and quantify neovascularisation in carotid artery plaques. Since this is one of the first studies systematically evaluating the ability of ultrasound in combination with air bubbles to evaluate neovascularisation in carotid artery plaques, the examination will be performed twice with an interval of 1/2 hour on the day before surgery, thus studying the reliability of the method. The second goal of this study is to investigate whether MRI at 3.0 T with a custom-designed 3T carotid coil, using a recently developed pulse sequence, is able to accurately identify and quantify neovascularisation. And the third goal of this study is to make an intermodality comparison of CE-US and MRI regarding their ability to identify and quantify plaque neovascularisation. |
||||
| Detailed Description | Atherosclerosis is a systemic disease of the large arteries and the leading cause of death in Western society. The development of atherosclerosis involves the accumulation of lipids, cells and extracellular matrix in the blood vessel wall. It is a progressive disease characterized by the formation of a fibrous cap by smooth muscle cell proliferation and migration, and the development of a necrotic/lipid core. This core develops due to the accumulation of lipids and apoptosis of lipid-loaded macrophages. In this process the intima, the innermost layer of the blood vessel, thickens. This will lead to narrowing of the lumen and obstruction of blood flow. The developed lesion of the vessel wall may become vulnerable to rupture of the fibrous cap. Cap rupture exposes the necrotic core to the blood leading to the formation of a thrombus. The thrombus may fully or partially obstruct the lumen and cause cardiovascular complications, such as myocardial infarction or stroke. Although atherosclerosis forms the origin of most cardiovascular diseases, at present much remains unknown of the atherogenic process. Therefore, it is essential that research is done to discover novel mechanisms of atherosclerotic development. Intimal neovascularisation has recently drawn much attention as a novel factor, likely contributing to atherosclerotic plaque growth and rupture. Neovascularisation occurs when the intima thickens and is associated with stenosis, plaque inflammation and hemorrhage. Because increased amount of neovascularisation may be associated with increased risk for stroke, it would be highly desirable to identify plaque neovascularisation by noninvasive imaging. At present, imaging of neovascular development in atherosclerotic lesions with conventional ultrasound is not feasible, since the vessel diameter is well below the resolution capacity of currently available ultrasound systems. Since almost a decennium, contrast-enhanced ultrasound (CE-US) with gaseous ultrasound contrast agents has been used for research purposes but is now also widely commercially available and registered for clinical use, which can be done safely. With the help of such a gaseous contrast medium containing air bubbles smaller than erythrocytes (microbubbles) it might be possible to depict neovascularisation in a carotid artery plaque, due to the strong signal that will be evoked even by a small number of air bubbles as compared to the signal from the surrounding tissue. So, the intensity increase of the ultrasound signal from the carotid artery plaque after administration of microbubbles might reflect the amount of neovascularisation. Until now, only case reports concerning this technique have been published, especially no comparison with histology has been performed. So, the first goal of this study is to investigate whether CE-US is able to accurately identify and quantify neovascularisation in carotid artery plaques. Since this is one of the first studies systematically evaluating the ability of ultrasound in combination with air bubbles to evaluate neovascularisation in carotid artery plaques, the examination will be performed twice with an interval of 1/2 hour on the day before surgery, thus studying the reliability of the method. Magnetic resonance imaging (MRI) is well suited for evaluating carotid plaques; it is widely available, provides excellent soft tissue contrast, multiplanar imaging capability, and is free of ionising radiation. Multisequence MRI has shown to be able to detect different carotid plaque components in vivo. However, only very little experience exists in identifying neovascularisation by MRI. Also, newer MRI systems (>1.5 T), newer coil systems, and better pulse sequences have recently become available. Therefore, the second goal of this study is to investigate whether MRI at 3.0 T with a custom-designed 3T carotid coil, using a recently developed pulse sequence, is able to accurately identify and quantify neovascularisation. Finally, the third goal of this study is to make an intermodality comparison of CE-US and MRI regarding their ability to identify and quantify plaque neovascularisation. |
||||
| Study Type ICMJE | Interventional | ||||
| Study Phase | Not Provided | ||||
| Study Design ICMJE | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
||||
| Condition ICMJE |
|
||||
| Intervention ICMJE | Drug: sulphur hexafluoride, gadopentate dimeglumine
CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine |
||||
| Study Arm (s) | 1
Patients with symptomatic 70-99% carotid stenosis who are operated on.
Intervention: Drug: sulphur hexafluoride, gadopentate dimeglumine |
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Estimated Enrollment ICMJE | 18 | ||||
| Completion Date | April 2010 | ||||
| Primary Completion Date | April 2010 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 18 Years and older | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | Netherlands | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00677963 | ||||
| Other Study ID Numbers ICMJE | MEC 08-2-019 | ||||
| Has Data Monitoring Committee | No | ||||
| Responsible Party | Werner H Mess/MD, PhD, Department of Clinical Neurophysiology, University Medical Center Maastricht | ||||
| Study Sponsor ICMJE | Maastricht University Medical Center | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | Maastricht University Medical Center | ||||
| Verification Date | April 2011 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||